- NewsCategory：
- All Company news Industry news
common83One result
-
1031
Gotham Therapeutics Establi shes Advanced Oncology Prσ÷¶ofiling Cascade with ProQinase to Progress its₹"↔ Portfolio of Epitranscriptom♣>©ic Drug Candidates
Gotham Therapeutics •→Establishes Advanced Oncol₹≠₹ogy Profiling Cascade with ProQinase to Prεogress its Portfolio of Epitra♠"φnscriptomic Drug CandidatesWEDNES↕✔↔DAY, OCTOBER 30, 2019Goth§×✘am Therapeutics, a biotechnology ≠≠company developing a novel dr<∏ug class targeting RNA-modifying proteins, and&'↔ ProQinase, an early stage drug-discov↑♥ery company, recently acquired b•¥©y Malvern/PA-based R∞≈≈eaction Biology Corp., today announced that theyπ↔ have established an array of advanced biochemicφ§al and cellular assays to characteriz↓$<>e epitranscriptomic-directed compounds.“₹β'↕Establishing tailored&→ target engagement, cell bi¥ εology, phenotypic, and in-vivo assays to evalua←γ↑πte compounds originating from our th§©εree most advanced epi£≠✔transcriptomic programs in parallel is a cruci>€al next step to develop our broad pipeline toλ±wards the clinic,” said Dr. Gerhard MüΩπ"↕ller, Chief Scientifi☆≈↔c Officer of Gotham The∏₩rapeutics. “By pursuing the≈ full range of the reader-writer-eraser↑↕ continuum, we are able to focus on targets wγ₩ ith the most compelling link★δ>•s to disease and advanc♣ε×e those programs in t™Ωandem.”“Combining our high proficiency inφ☆ providing customized solutions as early sta£☆ge drug-discovery servic♥ es, including tailor-made biochemical and cell-ba$sed assays, with Gotham’s expertise in epitr>∏anscriptomics, we were able to establish in a v✔÷ery short time a set of customized enzy£ matic and cellular assays for compounds add<≈σressing three different ★®mRNA-modifying targets,” said↕∞σ Dr. Sebastian Dempe, Chief Executive Officer o§≤f ProQinase. “We look forward to supporting Goth♥• am as the company advπances its programs into lead σ≥φoptimization and to cont∞®inued work with the Gotham team asΩ®₽sisting the company to adγ¥>vance its broad pipeliφ$ne in a time-effective ✔ manner.”In addition to establishing a ♣₽∞tailor-made profiling cascade ♠>♠for compounds from its three most advanced pr↕£☆ograms, Gotham has also made progress in®₩ strengthening its drug discovery enα€γ gine and developing its candidate base. G™≈otham previously complet♣✘ed the gene-to-lead phase for its d§>rug discovery project targeting the METTL3/ME≠✘TTL14 complex and established a ro≈↑₩πbust discovery process as a platform for future♦ ≠ projects. The company has also generate↔↑↕d a library of high-quality cαπλompounds tailor-made for accelerated hit gener✘≈• ation and hit-to-lead expansion against lar→™ge parts of the epitra ≥nscriptomic target space. T$¥ his library includes a collection of over 2,0&≠00 analogues covering over≈≤£≤ 80 distinct chemotypes that will be used to ↔©∏further accelerate Got™ ←ham’s drug discovery effα∏orts as it expands its pipelin≤±©e.The original link:https://www.p$¥∏☆harmafocusasia.com/news/gotham-therapeutic₩$↕s-establishes-advanced-oncoεδlogy-profiling-cascade-with-proqinas&↓÷e-to-progress-its-portfolio-of-epitrans©γ'criptomic-drug-candidates2019 Asia-pacific ph±§∑arma IP Leader Summit: http://e±☆n.zenseegroup.com/p/510934/will be held in& ©•nbsp;Beijing on November 14-1 σ♠5, and will attract more than 500 industry expeδ☆φλrts from domestic and foreiλ→πgn pharmaceutical companies,←≈ biotechnology companies, governments, associations, law firms,→π€♦ intellectual property ageφπnts and other companies→¶σ to attend.Official regis≤←tration and consultation chann✔σels:Contact：AnnPhone: 0€→∏21-65650305Email：Marke©♠©ting@zenseegroup.com'±http://en.zenseegroup.com/p/510934 -
1030
Gilead and Glympse Bio Announce Strategic Collab♥≤£oration for Use of Biomarker Technologyε$ in NASH Clinical De↕★₩<velopment
Gilead and Glympse Bio Announce Strategic Collabo≈✘ration for Use of Biomarker Technology inε<≤ NASH Clinical DevelopmentTUESDAY, ≤®OCTOBER 29, 2019Gilead Sciences Inc. an♥☆₩d Glympse Bio, Inc., todayδ announced that the companies have entered iΩnto a strategic colla₩<α♦boration in nonalcoholic steatohepatitis (NASH) c ±linical development. Glympse Bio’s proprie ✘α≈tary synthetic biomarkers – bioengineered to ★ identify stage and progres β♦sion of disease as well as early detection of tre<α÷↔atment response – will be used to dete×α≥→rmine clinical trial participants’§∞<× stage of disease at ini •tial screening and to determiπ★αne responses to study treatment"↕≤ in Gilead’s NASH clinical program.“We aα•re excited about the opportunity to partner withγδ™ Glympse Bio to help inform our NASH developm•¶✔£ent program,” said Mani Subrα•☆"amanian, MD, PhD Senior Vice Presiπ≠₽✘dent, Liver Diseases, Gilead Science ₩&s. “By utilizing thi×™♥→s innovative technology, we hope to bet₩©€₽ter characterize this co☆≥₩mplex disease and improve our understa✘ε÷ nding of how our compounds ↕≤≈•impact disease progression.”Glympse Bio’s p←£¶§roprietary technology, Glympse Inside™, combines¶λ'≤ synthetic biomarkers with₹×₩ machine learning approaches t♣<∑→o identify the stage and monit ∞βor progression of importa©nt, complex diseases suc↑ γh as cancer, fibrosis♦← , inflammation, and infections, in real time£≥πσ.“We are very excited about partnering with¥≥≥ Gilead, a leader in dru g development, to help drive earlier and more← γ☆ favorable outcomes for patients,” £β<•said Caroline J Loew, President and CEO, £↕♥Glympse Bio. “Gilead’s commitmenπ≤t to developing innovatiδ★₩δve medicines in areas of high unmet medical nee→¥₽d aligns with our mission of transforming diseas•"↕e detection and measuring treatment respon$$φ&se, all with the goal of helping improve the↓'§♥ lives of patients.”information source:pγ✔÷harma focus AsiaThe original link:https:h Ω$¥ttps:https://www.pharmafo±γ£cusasia.com/news/gilead-and-glympse-bi ¶o-announce-strategic-collabor ∞&≠ation-for-use-of-biomarker-technology-in✘♥-nash-clinical-development2←♣019 Asia-pacific pharma IP Leader Summit→∞:http://en.zenseegroup.com/p/51093÷Ωφ×4/ will be held in Beijinγ₽g on Novemb•₽Ωer 14-15, and will attract more than 500 industryΩ¥ experts from domestic and foreign pharmaceuti>∏$✘cal companies, biotec∑→hnology companies, governments, associatioγ"δns, law firms, intellectual prope÷¶δ<rty agents and other companies to attend.Offi✔±λcial registration and consultation channels:→φContact：AnnPhone: 021-65650305Email：Marke↔≈γting@zenseegroup.comhttp://en.zenseegroup.com/♣₹≈p/510934 -
1029
HistoIndex Announces Global Partnersh®↔₩ips To Expand AI-Based Di∏¶& gital Pathology Platform
HistoIndex Announces Global Partnerships © ∑♠To Expand AI-Based Digital Pa♠$₹ thology PlatformMONDAY, OCTOBER 28, 2019H☆ £≤istoIndex announces the expa←αnsion of its AI-based digital pathology '¥platform towards large§-scale NASH preclinical programs for ph♥•armaceutical and biotech companies to a¶♠↑λchieve quantifiable and reproducible data o₩γ₽n therapeutic responses in NASH animal ≈ models, and to aid CROs as well as rese∏¶±•arch agencies in validating new ≠←models mimicking the NASH π"β♥disease.Published preclinical studies have¥ demonstrated the use of HistoIndex'sΩσ→ fully quantifiable Second Haδ₽★σrmonic Generation (SHG) technology as →♠απa highly accurate stain-free method that c±©×an monitor the effic&Ω€acy of various thera★λ<peutic agents, by quantif"'β€ying more than 450 NASH-associated parameter≠$'αs in fibrosis, inflammation, bal✔×looning and steatosis. The information of t♣★hese NASH-associated parameters gathered fr™™→om the entire liver tissue, provides compreh♥♠$≤ensive insights on the ×☆∞Ωmechanism of action of the therapeutic agent.&nbs♠←♣p; As a drug discovery tool, HistoIndex's S€§✔HG-enabled digital pathology platform will allow •♣✔pharmaceutical and biotech Ω☆companies to select promising lea≤>★d candidates for further optimizatio∑∏→↕n and make informed decisions in the management ☆≠♥of their NASH drug develo¥δ§pment pipeline.In addition to ongoing NASH clini©α§∞cal trials, HistoIndex is c "↑urrently involved in multiple p♣★αreclinical studies, most of whicπγ≤•h are conducted by ma★≠★jor pharmaceutical and≤¶ biotech companies, medic∑al universities, CROs and research agencies.Ω&¥' Notably, HistoIndex has recently ≥γ≤entered into a collabo≤∑♠ration with the A*STAR's Genome Instεγ®itute of Singapore (GIS) to vali'¥date their in vivo and in vitro NA∞÷ SH models based on Asian-centri✘∏♠c clinical data. Says Professor Patrick Tan,×↕¶ Executive Director of the Genome Institu¶♣σ←te of Singapore (GIS), "At GIS, we conduct o →↔πur preclinical studies on fatty liv₽→☆&er involving data from animal models €πbased on patient-derived transcrip±∏tomic data. This has a high translational potent§¶•ial as it helps us to ₩↑'pinpoint new therapeuti✘"←c targets and their validat∑←®ion. Therefore, using a f€✔ully quantitative, reliable and>σ★≠ objective pathological evaluation such ₹&✔€as HistoIndex's AI-bas≈α☆ed digital pathology platform∞π≠β is essential to the success of our e∑↔☆≤fforts in therapeutic target εdiscovery."HistoIndex is also a partner wi>εth globally-renowned CRO, WuXi App₩tec, in advancing their•¶¶ NASH preclinical prog ✘₹εrams with advanced R&a™÷®¥mp;D and smart imaging analysis capabilitie$'→©s. Published study dα¶↔¶ata will be available for discussions during§≤¥ networking opportunities throughout AASLD's ×₩≤The Liver Meeting® in November 2019. "W™≤₹e are very excited to extend our AIΩ -based SHG platform to preclinical st§£↑udies to help companies with drug discovery prog©rams select promising lead ÷★ candidates for furthλ↑er optimization and subsequent clini"↓cal development," says Dr Poon Thong Yuen, Chief★↔ Executive Officer of HistoIndex. "Our SHG imageβ≈ analysis platform has already been us♥©≈↔ed to analyze the efficacy ∞∑of a series of promising drug<" candidates for NASH within various animal mode©±←ls commonly-used by the industry, and we belie✘≤ve these preclinical©γ partnerships will help driv¶£e the adoption of our platform significant→♠™≤ly."information source:pha™♦rma focus AsiaThe original link:https:htt÷☆ ♥ps://www.pharmafocusasia.co↔®→♥m/news/histoindex-announces-global-p∏≈artnerships-to-expand-ai-based-digεital-pathology-platform2♠×019 Asia-pacific pharma IP Leader$∑>" Summit: http://en.zenseegroup.com/p/51093♦¶δ4/will be held in Beijing Ωδ; on Novemb≈er 14-15, and will attr"✔≥<act more than 500 industry experts from domesti¥β™c and foreign pharmaceutical <↑λ♦companies, biotechnology companies, governments,→" associations, law firms, intellectual proper∑★ty agents and other companies to attend.Offi < cial registration and consultation channels:Co↕$≈₹ntact：AnnPhone: 021-656∞™↔₽50305Email：Marketing@zenseegroup.comhttp://en.zφ☆≤→enseegroup.com/p/5109®<✔ 34 -
1028
AVROBIO Receives Orphan-Drug Designation from th"↕®€e U.S. FDA for AVR‑RD‑02 for the T±§reatment of Gaucher Disease
AVROBIO Receives Orphan-✔•αDrug Designation from the U.S. FDA±₹↕ for AVR‑RD‑02 for the×→ Treatment of Gaucher D<≠<>iseaseFRIDAY, OCTOBER 25, 2019AVROBIO, Inc., t"≈oday announced that the U.S. Food©±↑ and Drug Administration (FDA) π≠↓✘has granted orphan-drug designation for the Com₹πpany’s investigational gene therapy, AVR-RD-0π✘2, for the treatment of Gaucher disease. AVR"✔"-RD-02 consists of the patient’₽↔↔s own hematopoietic stβ® em cells, genetically¥♣"↔ modified to express gl™∏₹ucocerebrosidase (GCase),↑↔• the enzyme that is deficient in Gaucher disease. The Company is actively recruiting in Canada f↕<"or its Phase 1/2 clinical t™™₩™rial of AVR-RD-02, which ©€♥≈seeks to evaluate the s ↕♣♠afety and efficacy of the the•φε&rapy in patients with Type 1 Gauch±×er disease.“Under the existing standard of ca↔§re, patients with Gaucher disσ↕♦≤ease are bound to a lifelong infusion sche £×dule of enzyme replacement th↕Ω£"erapies, and still experience painful×₹€✔ and progressive symptoms such a®↑s debilitating musculoskeleβ♦λ↓tal pain and fatigue,” said Birgitte Volck, ☆MD, PhD, President of Research and ± Ω≠Development at AVROBIO. “Orphan-drug designa×$σtion recognizes the unmet ne₩ed of populations with rare diε♦seases like Gaucher w÷✘✔here AVROBIO strives to transform ≠₹↓↓lives by addressing the underlying cause of t↑±≥he disease with a single dose of gene therapy. ≥Ω”Orphan-drug designatελion is granted by the FDA to drugs and biolo↑€γ×gics which are intended for the s••afe and effective treatment, diagnoπ∑sis or prevention of rare diseases or con♦×ditions that affect fewer than 200,000 peo÷$↑↑ple in the United States. Orphan-drug designaφ♥ tion provides certain in₩α©>centives, which may include tax cr§↑edits towards the cost of π€clinical trials and prescription d≠'♠≥rug user fee waivers.information←♥€ source:pharma focus AsiaThe o&≠£riginal link:https:https://www.pharmafσ>•ocusasia.com/news/avrobβ≤ io-receives-orphan-drug-designation-from-the-us-fπ≤∑↔da-for-avrrd02-for-the-treatment-of-gaucher-diseaα£se2019 Asia-pacific pharma I×σ₩P Leader Summit: http:/δ≥™©/en.zenseegroup.com/p/510934/will be hel←εd in Beijing on November 14-π15, and will attract mor±±e than 500 industry δ₽↓≥experts from domestic and ®'foreign pharmaceutical companies, biotech♦δnology companies, governments, associations→♣, law firms, intellectual property agents and oth✘•er companies to attend.Official regπ↕α✔istration and consultation channels:Contact：An☆÷nPhone: 021-65650305Emai←¥l：Marketing@zenseegroup.comht♦☆tp://en.zenseegroup.com/p/510934 -
1026
AZTherapies Strengthens Neuroinflammation-Targ♦≤≤πeted Pipeline Through Acquisition o±•≥f Smith Therapeutics
FRIDAY, OCTOBER 25, 2019AZTh←♥φ€erapies, Inc., a biopharmaceutic§ ✔→al company developing therapeutics↓$ to extend brain health, today announced the ®→$acquisition of Smith↕• Therapeutics, a private biophβ≥armaceutical company Ω×€≤with a shared goal of targeting neuroinfl¶∏ammation to treat neurodegenera"↓✔₹tive disease. Smith T§ herapeutics’ Founder and Chief Execu♥± tive Officer Philip Ashton-Rickardt, Ph.D., has ∞↓♥joined the senior leadership → team at AZTherapies as Senior Vice President of>φ§← Immunology. Financial terms of the acquis→β♠ ition were not disclosed.Smith$§ Therapeutics’ propr≤♥←♦ietary research platform focuses₹↕ on the use of modified ≈←"≤T cells to restore a healthy bala♥→♦nce of inflammatory and regulatory←π cells in the brain. To date, Smith haααs successfully engineered immunos♥≤♠uppressive T regulatory (Treg) ↑→★cells with Chimeric Antigen Re÷×±✘ceptors (CARs) targeting brai↔₽n glial cells. Previous research has demons α§∞trated the ability of Tregs to dampen microglia•♦→βl activity and reduce neuroinflammation in models π✔♦ of neurodegeneration, suggesting their✔σφ" potential utility in the tr<∑eatment of diseases inclu¥>φding Progressive Supranuclear Palsy (PSP), Alzh§£eimer’s disease, Parkinson’s disγ÷→ease, Huntington’s disease, σλ Amyotrophic Lateral Sclerosis (ALS), an€¥d others.“This acquisition represents a meaningfu♥'¶l step forward for us as we cont≤£γinue to strengthen our leadership positio↔™n in the development of therapies targetin↓←→g neuroinflammation to sto¥ p or slow the progression of neurodegenerat£ €ive diseases,” said David R. Elmaleh♣&", Ph.D., Founder, CEO, and Chairman of AZTherapi♦Ω₩es. “We are excited to be working with Philip & as we add this cutting-edge technology to our p♣αortfolio of innovativ♥±αe programs. An esteeme₽→✔₹d immunologist and inventor of the technol> ogy, Philip brings unparalleled→φπ expertise to the company γ ₹and we look forward to a¶dvancing this CAR-Treg program further int↓•ε∞o IND-enabling studies and into c★linical development as rapidly as possible.”D←←r. Ashton-Rickardt com∑>ππmented on the acquisitio€Ω ¥n and his appointment: “Our s≠α←hared rationale of targeting neur↑'♠oinflammation as the ro↓♠ot cause of neurodegenerative disea$♥≈se makes this acquisition a great stra↓±tegic fit for us. With AZTherapies’ expertis$¥e in drug development an£πd clinical trial execution, we believe that toge δεther, we are well position∑Ω>♥ed to advance our CA×ε¶✔R-Treg technology and fundamentally cha<✔γnge neurodegenerative disease progression.>"”Prior to launching Smith Therapeutics in 2017,♦™₽ Dr. Ashton-Rickardt was Chair in Immu§•Ω₽nology at Imperial Colleg§←₽↓e London, Visiting Professor, Brigha↑∑m and Women’s Hospital, Harvar¶÷≠d Medical School, and Associate Profe♠ ssor in the Department of Pathology at tββ he University of Chicago. His work ha→¥$βs been recognized by his peeδ↕☆rs through the award of tenure f©••rom The University of Chicago an∞™φd by his fellow citizens as a recipient<₹ ♥ of the Early Career Awar÷<φd for Scientists and Engineers ★♠γ€from President Bill Clinton. He has published×₩ more than 65 peer-reviewed papers in more ¥☆≠than 30 academic journaπ$ ls (including Cell, Science, Immunity, andγ' Nature Immunology), has served as an ed☆≤itor for several academic jo$ ★₽urnals, and has been• × a member of grant rev÷↕±iew boards globally. Dr. Ashton-Rickardt recei↕÷βved a B.Sc. in Biochemistry from the Universi→¶λ©ty of London, King’s Collegeσ with honors, a Ph.D. in Molecul¥λβar Biology from the Un↔☆✘iversity of Edinburgh, and completed post-doct£ →oral work at the University €of Edinburgh and the Massachusetts Instπ±>itute of Technology in Molecular Biology™€ and Molecular Immunology, respectively.in¥♦>formation source:pharma focus AsiaT↔♣he original link:https:https:/αδ/www.pharmafocusasia.com/news/azthera☆±☆pies-strengthens-neuroin✔π→★flammation-targeted-pipeline-through-acquis∞¥↕₩ition-of-smith-therapeutics2019 As←§£ia-pacific pharma IP Leader Summit: h$∑ttp://en.zenseegroup.com/p/510×♣✘934/will be held in Beijing &✘♠≈←nbsp;on November 14-15, and♣≥ will attract more than 500 industry experts γ'γfrom domestic and foreign pharmaceutical ♣companies, biotechnology companies, governme¶±nts, associations, law firms, inte¶♣¥llectual property agents and other companies±Ω to attend.Official registration and cons✘>ultation channels:Contact：AnnPhone: 0'♣€∑21-65650305Email：Marke↔φting@zenseegroup.comhttp:σ→//en.zenseegroup.com/p/510934♦"
Contact Us
Zensee_Daystar online
© 2011-2016